Ripple XRP ETFs Hit $1.32B in Inflows — Why the Token Still Hasn’t Caught Up

May 10, 2026
XRP ETF Hype Meets a Reality Check as Inflows Break Near $1.40

New York, May 10, 2026, 14:06 EDT

U.S. spot XRP exchange-traded funds drew $6.04 million in net inflows on May 8, lifting cumulative net inflows to $1.325 billion as investors kept adding regulated exposure to Ripple-linked XRP products. Canary Capital’s XRP ETF, XRPC, was the only fund with a net inflow for the day and has now drawn $438 million historically, according to a ChainCatcher report carried by Bitget that cited SoSoValue data.

The timing matters. The latest flow followed a three-day May inflow streak worth about $28.1 million between May 4 and May 6, keeping the XRP ETF trade alive even after the token struggled to hold earlier gains. The funds have logged positive weekly flows in about 77% of weeks since their November 2025 launch, with outflows in six weeks, 24/7 Wall St. reported in an article syndicated by Yahoo Finance.

Franklin Templeton’s XRPZ added to the same split picture. TipRanks said the Franklin XRP ETF drew $5.42 million on May 7, equal to about 2.1% of its $257.1 million in assets under management, while XRP traded at $1.4284 and carried a one-day technical “Sell” signal. That is not a broad risk-on rush. It looks more like selective positioning. TipRanks

A spot ETF is a listed fund that gives investors exposure to the underlying asset without requiring them to hold the token directly. Canary says XRPC seeks to provide exposure to the value of XRP held by the trust, less expenses and liabilities; Canary’s ETF FAQ says digital-asset ETFs trade on public exchanges and can be bought or sold through most brokerage platforms.

XRP itself was trading around $1.50, up 5.76% over 24 hours, with a market value of about $92.9 billion and a No. 4 ranking among cryptocurrencies, CoinMarketCap data showed. That rebound gives the ETF flows some support, but it does not erase the tension between fresh fund demand and a token still well below prior cycle highs.

The inflow data landed the same week Ondo Finance said it had completed a near-real-time cross-border redemption of tokenized U.S. Treasuries with Kinexys by J.P. Morgan, Mastercard and Ripple. Tokenization means representing a traditional asset, such as a Treasury fund, on a blockchain; Ondo said the XRP Ledger processed the asset leg in under five seconds. Ondo President Ian De Bode called it a move toward “24/7 global markets,” while RippleX executive Markus Infanger said the pilot showed institutions could run cross-border transactions as a “single, integrated flow.” PR Newswire

That is the broader pitch behind XRP ETF demand: regulated access to a token whose backers argue it has a payments and settlement use case, not just a trading story. In an April background post, Ripple cited Bitwise Chief Investment Officer Matt Hougan as saying the launch showed “significant demand for unique assets,” with investors using XRP ETFs alongside bitcoin and ethereum exposure. Ripple

Franklin’s own product page shows XRPZ had $263.17 million in total net assets as of May 10 and seeks generally to reflect the price of XRP before expenses. The fund listed on NYSE Arca on Nov. 24, 2025, and shows a gross sponsor fee of 0.19%, with a net sponsor fee listed at zero on the current page.

But the risk is plain. Franklin’s factsheet says XRPZ is not a direct investment in XRP, holds only XRP and cash, is not diversified, and may be more volatile than broader portfolios. It also warns that digital-asset markets in the U.S. remain exposed to regulatory uncertainty and that ETF or ETP shares can trade above or below net asset value.

For now, the market signal is split. Cash is still moving into XRP ETFs, but the strongest daily flow came from one issuer, and XRP’s own price action has not yet shown the kind of clean follow-through that would turn ETF demand into a broader rally. The next test is whether flows widen beyond Canary and Franklin — and whether token buyers follow the fund buyers.

Stock Market Today

  • Amplia Therapeutics Expands Narmafotinib Trials with New Ovarian Cancer Study amid Strong Pancreatic Results
    May 10, 2026, 2:15 PM EDT. Amplia Therapeutics (ASX:ATX) has launched a new trial for its drug narmafotinib targeting ovarian cancer, partnering with the Australia New Zealand Gynaecological Oncology Group (ANZGOG). This expands the drug's potential beyond pancreatic cancer, where it showed a 35.9% response rate in the ACCENT trial, outperforming standard benchmarks. Narmafotinib blocks focal adhesion kinase (FAK), a protein aiding tumor resistance to chemotherapy in both cancers. The PRROSE ovarian study will enroll 15-20 patients with resistant high-grade serous ovarian cancer. Amplia's partnership with ANZGOG reduces trial costs and boosts clinical reach. Although the AMPLICITY pancreatic trial paused recruitment due to FOLFIRINOX-related toxicities, Amplia is exploring alternative combinations. FY25 revenue was A$3.78 million with losses of A$6.57 million. The ovarian trial adds strategic breadth, while pancreatic data remains the primary value driver.